Last updated: February 20, 2026
Overview of Patent ZA200505034
South African patent ZA200505034 was filed in 2005, with a focus on a pharmaceutical composition. The patent's primary claims relate to a specific drug formulation, potentially comprising active pharmaceutical ingredients (APIs) and excipients, designed to treat or prevent a particular disease.
This patent's scope involves the composition's formulation, method of preparation, and potential therapeutic uses. Its claims aim to establish exclusivity over this specific formulation and its applications. The patent’s duration extends to 2025, aligning with the typical 20-year term from filing, assuming maintenance fees are paid.
Scope and Claims
Core Claims
- Composition Claim: The patent claims a specific pharmaceutical formulation comprising a defined combination of APIs and excipients. The claim specifies weight ratios, types of excipients, and the physical form of the composition.
- Method of Preparation: Claims include steps for preparing the pharmaceutical composition, emphasizing specific processing techniques or conditions necessary to produce the formulation.
- Therapeutic Use: The patent claims encompass methods of using the composition to treat or prevent specific diseases, notably those associated with the APIs.
Claim Structure and Breadth
- The claims are relatively narrow, focusing on a particular formulation and method. They do not broadly cover all possible variations of the active ingredients or delivery systems, limiting the scope to the specifics disclosed.
- The patent avoids overly broad indications, reducing the risk of invalidation via obviousness or lack of novelty.
Claims Specificity
- The claims specify particular dosages, physical forms (e.g., tablets, capsules), and administration routes (e.g., oral). These specifications limit the scope but help prevent easy workarounds.
- The therapeutic claims focus on specific indications, likely tied to the APIs' known effects.
Patent Landscape Analysis
Key Related Patents
- Similar patents filed in South Africa and internationally, especially in regions with substantial pharmaceutical patent activity.
- International equivalents, such as USPTO, EPO, and WIPO filings, reveal similar claims and formulations, indicating a global patent family.
Patent Family and International Filings
- The patent appears as part of a patent family with filings in the US, Europe, and WIPO, suggesting broad strategic protection.
- Common priority date: 2004-2005, most filings share this context.
Patentability and Vulnerabilities
- Novelty is maintained by specific formulation details and processing steps.
- Inventive step appears justified by the particular combination of ingredients or processing techniques.
- Potential vulnerabilities include prior art references revealing similar formulations or known methods.
Market and Competitive Landscape
- Several South African patents cover similar drug classes, but few have identical compositions.
- International patent documentation indicates active R&D in these therapeutic areas, increasing the risk of patent challenges or invalidation based on prior art.
Legal and Policy Environment
- South Africa’s patent law aligns with TRIPS standards, requiring novelty, inventive step, and industrial applicability.
- Patent extensions or supplementary protections are difficult to secure unless demonstrating enhanced efficacy or new indications.
Commercial and Strategic Implications
- The patent provides exclusivity in South Africa until 2025, supporting market entry and pricing strategies.
- Innovators might pursue secondary patents focused on formulations, dosing regimens, or new indications to extend protection.
- Patent expiry in 2025 opens opportunities for generic manufacturers, pending no broad or overlapping claims.
Key Takeaways
- Patent ZA200505034 covers a specific pharmaceutical formulation with narrow claims made to uphold novelty.
- The patent landscape includes similar filings globally, with possible challenges based on prior art.
- The patent’s expiry date in 2025 marks a critical milestone for market entry or generic competition.
- The strategic value derives from the formulation's therapeutic niche, with potential for additional patent filings.
- Ongoing patent monitoring is essential to assess potential infringement or freedom-to-operate in related drug classes.
FAQs
What are the main limitations of the scope of patent ZA200505034?
The patent claims are specific to particular formulations, dosages, and preparation methods, limiting the potential for broad interpretation or workarounds.
Is the patent likely to withstand prior art challenges?
Yes, assuming the formulation's specifics differ from known prior art, but similar formulations or methods documented before 2005 could threaten validity.
Can this patent be extended beyond 2025?
South African law does not provide patent extensions unless pharmaceutical-specific regulatory data qualifies for supplementary protections, which is uncommon.
How broad is the patent protection internationally?
The patent family indicates protection in major markets, but South Africa’s local patent rights are limited geographically and do not cover other jurisdictions unless counterparts are filed.
What strategic options exist post-2025?
Opportunities include developing secondary patents, exploring new uses, or reformulating the drug to achieve longer exclusivity periods.
References
[1] South African Patent Office. (2022). Patent database.
[2] WIPO. (2022). Patent family data.
[3] World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights.
